SAN
DIEGO, March 25, 2024 /PRNewswire/ --
DiCello Levitt LLP reminds investors that they have until the
April 9, 2024 deadline to file
their application for appointment as lead plaintiff in the
shareholder class action lawsuit against Amylyx Pharmaceuticals,
Inc. ("Amylyx" or the "Company") (NASDAQ: AMLX). This action is
pending in the United States
District Court for the Southern District of New York.
If you purchased shares of Amylyx securities between
November 11, 2022 and November 8, 2023, and would like to discuss your
legal rights and how this case might affect you and your right to
recover your losses, you may, without obligation or cost to you,
contact DiCello Levitt partner Brian
O'Mara by calling (888) 287-9005 or at
investors@dicellolevitt.com. You may also learn more at
https://dicellolevitt.com/securities/amylyx-pharmaceuticals/. If
you wish to serve as a lead plaintiff in this class action, we can
help you petition the Court by the April 9,
2024 deadline.
Case Allegations: The Amylyx lawsuit alleges
that defendants made false and/or misleading statements and/or
failed to disclose that: (i) Amylyx had overstated RELYVRIO's
commercial prospects; (ii) patients were discontinuing treatment
with RELYVRIO after six months; (iii) the rate at which new
patients were starting treatment with RELYVRIO was decreasing; (iv)
Amylyx had also overstated RELYVRIO's prescription rate; and (v)
Amylyx hid the foregoing negative trends from investors and the
market by blocking analysts from viewing RELYVRIO's prescription
data.
When the market learned the truth about the foregoing, Amylyx's
stock price fell $5.74 per share, or
31.89%, to close at $12.26 per share
on November 9, 2023.
No Class Has Been Certified. Until a class is certified, you are
not represented by counsel unless you retain one. You may select
counsel of your choice. You may also remain an absent class member
and do nothing at this point. An investor's ability to share in any
potential future recovery is not dependent upon serving as lead
plaintiff.
About DiCello Levitt:
At DiCello Levitt, we are dedicated to achieving justice for our
clients through securities, class action, business-to-business,
public client, whistleblower, personal injury, civil and human
rights, and mass tort litigation. Our lawyers are highly respected
for their ability to litigate and win cases—whether by trial,
settlement, or otherwise—for people who have suffered harm, global
corporations that have sustained significant economic losses, and
public clients seeking to protect their citizens' rights and
interests. Every day, we put our reputations—and our capital—on the
line for our clients.
DiCello Levitt has achieved top recognition as 2023 Plaintiffs
Firm of the Year and 2023 Trial Innovation Firm of the Year by the
National Law Journal, in addition to its top-tier
Chambers and Benchmark ratings. For more information
about the Firm, including recent trial victories and case
resolutions, please visit www.dicellolevitt.com.
Attorney Advertising. Prior results do not guarantee a similar
outcome.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/investor-alert-amylyx-pharmaceuticals-inc-nasdaq-amlx-investors-with-losses-of-more-than-100-000-encouraged-to-seek-appointment-as-lead-plaintiff--april-9--2024-deadline-302097227.html
SOURCE DiCello Levitt LLP